JP2014518275A5 - - Google Patents

Download PDF

Info

Publication number
JP2014518275A5
JP2014518275A5 JP2014519145A JP2014519145A JP2014518275A5 JP 2014518275 A5 JP2014518275 A5 JP 2014518275A5 JP 2014519145 A JP2014519145 A JP 2014519145A JP 2014519145 A JP2014519145 A JP 2014519145A JP 2014518275 A5 JP2014518275 A5 JP 2014518275A5
Authority
JP
Japan
Prior art keywords
composition
meibomian gland
glucocorticoid
weight
azalide antibiotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014519145A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014518275A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/044949 external-priority patent/WO2013003731A2/en
Publication of JP2014518275A publication Critical patent/JP2014518275A/ja
Publication of JP2014518275A5 publication Critical patent/JP2014518275A5/ja
Pending legal-status Critical Current

Links

JP2014519145A 2011-06-29 2012-06-29 再発性マイボーム腺障害の処置方法およびそれによる再発頻度の減少方法 Pending JP2014518275A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161502490P 2011-06-29 2011-06-29
US61/502,490 2011-06-29
PCT/US2012/044949 WO2013003731A2 (en) 2011-06-29 2012-06-29 Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence

Publications (2)

Publication Number Publication Date
JP2014518275A JP2014518275A (ja) 2014-07-28
JP2014518275A5 true JP2014518275A5 (enExample) 2015-08-06

Family

ID=47424819

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014519145A Pending JP2014518275A (ja) 2011-06-29 2012-06-29 再発性マイボーム腺障害の処置方法およびそれによる再発頻度の減少方法

Country Status (6)

Country Link
US (1) US20140142055A1 (enExample)
EP (1) EP2726081A4 (enExample)
JP (1) JP2014518275A (enExample)
KR (1) KR20140054002A (enExample)
CA (1) CA2840626A1 (enExample)
WO (1) WO2013003731A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7981145B2 (en) 2005-07-18 2011-07-19 Tearscience Inc. Treatment of meibomian glands
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
US8915253B2 (en) 2005-07-18 2014-12-23 Tearscience, Inc. Method and apparatus for treating gland dysfunction employing heated medium
US20090043365A1 (en) 2005-07-18 2009-02-12 Kolis Scientific, Inc. Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma
US7981095B2 (en) 2005-07-18 2011-07-19 Tearscience, Inc. Methods for treating meibomian gland dysfunction employing fluid jet
US20080114423A1 (en) 2006-05-15 2008-05-15 Grenon Stephen M Apparatus for inner eyelid treatment of meibomian gland dysfunction
US20070060988A1 (en) 2005-07-18 2007-03-15 Grenon Stephen M Melting meibomian gland obstructions
WO2013003594A2 (en) 2011-06-28 2013-01-03 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US8128674B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction
US8137390B2 (en) 2006-05-15 2012-03-20 Tearscience, Inc. System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction
US8128673B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
CN104011073B (zh) 2011-10-18 2017-08-25 科荣生生物科学公司 使用氨基酸稳定的依那西普制剂
US10842670B2 (en) 2012-08-22 2020-11-24 Johnson & Johnson Vision Care, Inc. Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices
US10130507B2 (en) 2013-08-03 2018-11-20 Michael C. Whitehurst Dry eye treatment device
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
CN108472312A (zh) * 2015-09-28 2018-08-31 阿祖拉眼科有限公司 用于增加睑板腺脂质分泌物的含硫醇及二硫化物的药剂
MA44676A (fr) 2016-04-14 2019-02-20 Azura Ophthalmics Ltd Compositions de disulfure de sélénium destinées à être utilisées dans le traitement du dysfonctionnement de la glande de meibomius
WO2018178769A1 (en) * 2017-03-29 2018-10-04 M.G. Therapeutics Ltd. Agents for increasing meibomian gland lipid secretion
KR101895321B1 (ko) 2017-04-24 2018-09-05 주식회사 이루다 눈꺼풀의 분비샘 이상에 대한 치료장치
US11759472B2 (en) * 2017-11-21 2023-09-19 Cs Pharmaceuticals Limited Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
EP3955937A4 (en) 2019-04-18 2023-01-18 Azura Ophthalmics Ltd. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
EP4087655A4 (en) 2020-01-10 2024-02-21 Azura Ophthalmics Ltd INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY
CN116940570A (zh) * 2020-10-21 2023-10-24 阿祖拉眼科有限公司 用于治疗眼部病症的化合物和方法
IL302173A (en) * 2020-10-21 2023-06-01 Azura Ophthalmics Ltd Compounds and methods for the treatment of ocular disorders
EP4247367A4 (en) 2020-11-23 2024-10-16 Sight Sciences, Inc. Formulations and methods for treating conditions of the eye
WO2022180568A1 (en) * 2021-02-25 2022-09-01 Sun Pharmaceutical Industries Limited Dexamethasone for treatment of blepharitis
US20250275916A1 (en) * 2024-03-04 2025-09-04 Ocusoft, Inc. Medicated eyelid cleansing compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239113B1 (en) * 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US8372814B2 (en) * 2004-06-07 2013-02-12 Ista Pharmaceuticals, Inc. Ophthalmic formulations and uses thereof
EP2089035A1 (en) * 2006-11-02 2009-08-19 Riolan Technologies, Inc. Method for treating blepharitis
US10105441B2 (en) * 2007-08-16 2018-10-23 The Schepens Eye Research Institute, Inc. Method for inhibiting or reducing dry eye disease by IL-1Ra
US7795231B2 (en) * 2007-10-04 2010-09-14 Insite Vision Incorporated Concentrated aqueous azalide formulations
EP2313103B1 (en) * 2008-07-10 2014-06-18 Inspire Pharmaceuticals, Inc. Method of treating blepharitis
US10201548B2 (en) * 2009-03-06 2019-02-12 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
PL2493474T3 (pl) * 2009-10-30 2020-03-31 Intratus, Inc. Sposoby i kompozycje do podtrzymywanego dostarczania leków

Similar Documents

Publication Publication Date Title
JP2014518275A5 (enExample)
JP2018193377A5 (enExample)
BR112015009504A2 (pt) inibidores de rock
BR112012018500A2 (pt) alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
JP2017518302A5 (enExample)
JP2015524849A5 (enExample)
MY166890A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
PH12014500472A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
HK1209633A1 (en) Compositions and methods for treating diabetes
EP4140487A8 (en) Combination therapy for treating cancer
WO2009044392A3 (en) Novel sirna structures
PH12014500239A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP4397372A3 (en) Methods of treating lennox-gastaut syndrome using fenfluramine
RU2017134443A (ru) Способ лечения с применением традипитанта
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害(adhd)の治療方法
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
EP3069720A8 (en) Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases
WO2016090024A3 (en) Combination therapy for treatment of cancer
JP2018509388A5 (enExample)
CA2854430C (en) Liposomal corticosteroids for treatment of inflammatory disorders in humans
MX366497B (es) Cepas de bacteriófagos capaces de producir una infección lítica en una cepa de escherichia coli adherente-invasiva y su uso para el tratamiento de enfermedades inflamatorias intestinales.
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
EA201790563A8 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
MX2023014484A (es) Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion.